Floatz logo

141 assets in Hodgkins Lymphoma

Therapeutic assets addressing Hodgkins Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Camustine
Hodgkins Lymphoma
VIVUS LLCP2BBB (74)
Carboplatin
Hodgkins Lymphoma
St. Petersburg State Pavlov Medical UniversityP2BBB (74)
Cyclosporin A
Hodgkins Lymphoma
City of Hope Medical CenterP3BBB (73)
Isocyclophosphamide
Hodgkins Lymphoma
St. Petersburg State Pavlov Medical UniversityP3BBB (73)
Vinblastine
Hodgkins Lymphoma
M.D. Anderson Cancer CenterP4BBB (72)
Vincristine Sulfate
Hodgkins Lymphoma
National Cancer Institute (NCI)P3BBB (72)
Vinorelbine Ditartrate
Hodgkins Lymphoma
Michael Spinner, MDP3BBB (72)
Bleomycin
Hodgkins Lymphoma
National Cancer Institute (NCI)P4BB (71)
Dacarbazine
Hodgkins Lymphoma
M.D. Anderson Cancer CenterP4BB (71)
Methotrexate
Hodgkins Lymphoma
Therapeutic Advances in Childhood Leukemia ConsortiumP3BB (71)
Adriamycin
Hodgkins Lymphoma
M.D. Anderson Cancer CenterP4BB (70)
Pegfilgrastim
Hodgkins Lymphoma
Michael Spinner, MDP3BB (70)
Plerixafor
Hodgkins Lymphoma
Thomas Jefferson UniversityP2BB (70)
Cediranib
Hodgkins Lymphoma
M.D. Anderson Cancer CenterP3BB (69)
Cyclophosphamide
Hodgkins Lymphoma
Michael Spinner, MDP3BB (69)
Etoposide
Hodgkins Lymphoma
Memorial Sloan Kettering Cancer CenterP3BB (69)
Prednisone
Hodgkins Lymphoma
National Research Center for Hematology, RussiaP3BB (69)
Brentuximab Vedotin
Hodgkins Lymphoma
University of CologneP4BB (68)
Ruxolitinib
Hodgkins Lymphoma
Seda S. ToluP2BB (68)
(+)-Vincristine
Hodgkins Lymphoma
National Research Center for Hematology, RussiaP3BB (68)
Favezelimab
Hodgkins Lymphoma
Merck Sharp & Dohme LLCP2BB (67)
Fludeoxyglucose
Hodgkins Lymphoma
National Cancer Institute (NCI)P3BB (66)
Nivestim
Hodgkins Lymphoma
Thomas Jefferson UniversityP3BB (66)
Busulfanum
Hodgkins Lymphoma
City of Hope Medical CenterP2BB (65)
Fludarabine
Hodgkins Lymphoma
M.D. Anderson Cancer CenterP3BB (65)
Tacrolimus
Hodgkins Lymphoma
Memorial Sloan Kettering Cancer CenterP3BB (65)
Basiliximab
Hodgkins Lymphoma
City of Hope Medical CenterP2BB (64)
Cis-Diamminedichloroplatinum Ii
Hodgkins Lymphoma
Stichting Hemato-Oncologie voor Volwassenen NederlandP3BB (64)
Cytarabine
Hodgkins Lymphoma
Therapeutic Advances in Childhood Leukemia ConsortiumP3BB (64)
Dexasone
Hodgkins Lymphoma
University of CologneP3BB (64)
Procarbazine
Hodgkins Lymphoma
National Cancer Institute (NCI)P3BB (64)
Romidepsin
Hodgkins Lymphoma
Memorial Sloan Kettering Cancer CenterP2BB (64)
Gm-Csf
Hodgkins Lymphoma
Medical College of WisconsinP2B (63)
Sirolimus
Hodgkins Lymphoma
University of BirminghamP3B (63)
Bendamustine
Hodgkins Lymphoma
University Hospital, BordeauxP4B (62)
Lenalidomide
Hodgkins Lymphoma
M.D. Anderson Cancer CenterP2B (62)
Melphalan
Hodgkins Lymphoma
Thomas Jefferson UniversityP2B (62)
Pembrolizumab
Hodgkins Lymphoma
Michael Spinner, MDP3B (62)
Rituximab
Hodgkins Lymphoma
Beijing Children's HospitalP3B (62)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
Hodgkins Lymphoma
Fred Hutchinson Cancer CenterP2B (61)
Thiotepa
Hodgkins Lymphoma
Memorial Sloan Kettering Cancer CenterP2B (61)
Nivolumab
Hodgkins Lymphoma
M.D. Anderson Cancer CenterP3B (60)
Prednisolone
Hodgkins Lymphoma
National Cancer Institute (NCI)P3B (60)
Clofarabine
Hodgkins Lymphoma
Memorial Sloan Kettering Cancer CenterP2B (59)
Tislelizumab
Hodgkins Lymphoma
Xiuhua SunP4B (59)
Ipilimumab
Hodgkins Lymphoma
Dana-Farber Cancer InstituteP2B (58)
Mesna
Hodgkins Lymphoma
St. Jude Children's Research HospitalP2B (58)
Oxaliplatin
Hodgkins Lymphoma
OHSU Knight Cancer InstituteP2B (58)
Decitabine
Hodgkins Lymphoma
National Cancer Institute (NCI)P2/3B (56)
Hydrocortisone
Hodgkins Lymphoma
Therapeutic Advances in Childhood Leukemia ConsortiumP2B (56)
Showing 1 to 50 of 141 assets
PreviousPage 1 of 3Next